From Wikipedia, the free encyclopedia
Clinical data
Routes of
Subcutaneous injection

PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2][3] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][3] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][3] The drug has reportedly been in pre-clinical development for all medical indications since 2008.[1] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[2] The chemical structure of PL-6983 has yet to be made public.

See also


  1. ^ a b c Natasha Mitchner (2009). Hypoactive Sexual Desire Disorder in Women: Implications for Family Practice (PDF). Dowden Health Media. 
  2. ^ Simon JA (2009). "Opportunities for intervention in HSDD" (PDF). J Fam Pract. 58 (7 Suppl Hypoactive): S26–30. PMID 19825316. 
  3. ^ a b c Michael L. Krychman; Sandra Finestone (25 October 2010). 100 Questions & Answers About Breast Cancer Sensuality, Sexuality and Intimacy. Jones & Bartlett Publishers. pp. 120–. ISBN 978-1-4496-1936-7. 

External links

  • PL-6983 for Sexual Dysfunction - Palatin Technologies
  • PL-6983 for Female Sexual Dysfunction - Palatin Technologies
  • Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News
  • Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight

Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "PL-6983"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA